We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
628. Cancer Immunotherapy Against Murine Squamous Cell Carcinoma with Dendritic Cells Activated by Sendai Virus.
- Authors
Matsunaga, Akinao; Ueda, Yasuji; Yoneyama, Yasuo; Akutsu, Yasunori; Shimada, Hideaki; Kato, Tomonori; Okano, Shinji; Shibata, Satoko; Hasegawa, Mamoru; Yonemitsu, Yoshikazu; Sueishi, Katsuo; Ochiai, Takenori
- Abstract
[Background] Antigen-presenting cells, particularly dendritic cells (DCs) are important elements of antigen-specific adaptive immunity. Antigen-loaded DCs have now been used as a vaccine to improveimmunity against various cancer. However, the efficacy of therapeutic vaccination against cancer using DCs in the current clinical studies has been limited because of inadequate DC treatment, lack of established administration routes of DCs or uncomfortable environment to DC around tumor. We here report a novel method to activate DCs ex vivo by use of recombinant Sendai virus (SeV) for cancer immunotherapy. In vitro treatment with SeV led DCs to highly activated levels as indicated by surface markers, such as co-stimulatory molecules. We examined efficacy of SeV-activated DCs against murine squamous carcinoma (SCC VII).[Method]Lineage-negative cells, which were obtained from bone marrow of C3H mice, were cultured in the presence of GM-CSF and IL-4, and on Day 7 DCs were harvested. DCs were pulsed with tumor lysate (DCs : tumor cell for lysate = 1 : 3) for 18 hours, and then were infected with SeV (MOI = 40) for 8 hours. After 48 hours of SeV infection, surface markers such as CD11c, CD40, CD80, CD86, and MHC class II were analyzed by Flow cytometer. Intradermal implantation (C3H for 1 × 106 SCC VII cells) was done onto the abdomen on Day 0, and aforementioned 106 DCs were intratumorally implanted on Day 10 (tumor diameter = 5–8 mm), 17 and 24. The size of tumors was assessed three times a week.[Result]Transfection efficacy of SeV to CD11c positive cells from murine bone marrow was an around 85% at MOI 40 and most of the infected cells were highly positive of CD40, CD80 and CD86. The class II expression of such cells was also accelerated by infection by SeV. The tumor growth was efficiently disturbed by SeV activated DC immunotherapy. In case of this regimen, 2 of 6 mice completely eliminated the tumor. These results indicate that recombinant SeV is a new and powerful tool as an immune booster for DC based cancer immunotherapy.Molecular Therapy (2006) 13, S242–S242; doi: 10.1016/j.ymthe.2006.08.703
- Subjects
CANCER treatment; SENDAI virus; SQUAMOUS cell carcinoma; GENETIC transformation; TUMOR growth
- Publication
Molecular Therapy, 2006, Vol 13, pS242
- ISSN
1525-0016
- Publication type
Article
- DOI
10.1016/j.ymthe.2006.08.703